Skip to content

A Study Collecting Health Information to Understand and Prevent Gastric Cancer

Gastric Cancer Prevention: Understanding Precursor Lesions and Risk Factors for Progression to Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06370143
Enrollment
3200
Registered
2024-04-17
Start date
2024-04-11
Completion date
2036-04-11
Last updated
2026-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysplasia, Gastric Adenocarcinoma, Gastric Atrophy, Gastric Cancer, Gastric Intestinal Metaplasia

Keywords

Gastric cancer, gastric adenocarcinoma, gastric atrophy, Gastric Intestinal Metaplasia, dysplasia, Memorial Sloan Kettering Cancer Center, 24-083

Brief summary

The purpose of this study is to create a registry of participants with precursor lesions for gastric cancer, including gastric atrophy, intestinal metaplasia, and dysplasia. Normal controls and individuals with gastric cancer for comparison of baseline characteristics will also be enrolled.

Interventions

BEHAVIORALQuestionnaire

The questionnaire on clinical, environmental, lifestyle, and dietary risk factors will be administered

Sponsors

Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age ≥ 18 years old * Able to read and understand English and Spanish * Meet criteria for one of three potentially eligible study populations: * Individuals with gastric atrophy, gastric intestinal metaplasia, or dysplasia: Had a previous diagnosis of or have been diagnosed by the investigation team with gastric atrophy, gastric intestinal metaplasia, or dysplasia of the gastric mucosa on pathology review from an endoscopic biopsy. Individuals who have a prior history of early gastric cancer may be included, if they were treated endoscopically and have no evidence of disease. Individuals who have a prior history of a cancer other than upper gastrointestinal cancer may also be included, if they have no evidence of disease for at least 1 year prior to study enrollment and are not undergoing active treatment for any malignancy at any time throughout the study period * Healthy controls (average risk): Individuals with no history of cancer or gastric precursor lesions undergoing a clinically indicated endoscopy at MSK for workup or dyspepsia or reflux * Gastric cancer cases: Individuals with a known diagnosis of early gastric adenocarcinoma undergoing surgical resection at MSK

Exclusion criteria

* Age \< 18 years old * Women who are pregnant (may be enrolled after delivery) * Individuals with a prior history of upper gastrointestinal surgery or a prior cancer who are undergoing active treatment for malignancy or have been diagnosed within 1 year prior to the study enrollment or with pancreatic cancer. (This does not include incidentally diagnosed primary gastric adenocarcinoma identified during study follow up. Individuals diagnosed with gastric carcinoid limited to the stomach will also be included, given their ongoing parallel risk for gastric adenocarcinoma.) * Have severe comorbidities with expected survival time \<2 years or which would prevent them from undergoing routine elective EGD (at the discretion of the patient's provider and the study team) * Individuals having Hereditary Diffuse Gastric Cancer Syndrome, mutations including CDH1 and CTNNA1, or more than one genetic mutation * Exclude high risk esophageal and duodenal lesions including: * Duodenal Adenoma * Dysplasia or cancer at the esophagus or gastroesophageal junction * Patients with an increased risk for biopsies during EGD, such as those with clotting disorders.

Design outcomes

Primary

MeasureTime frameDescription
Creation of participant registryUp to 10 yearsThe primary objective of this study is to create a registry of individuals with precursor lesions for gastric cancer, including gastric atrophy, intestinal metaplasia, and dysplasia. Normal controls and individuals with gastric cancer for comparison of baseline characteristics will also be enrolled.

Countries

United States

Contacts

CONTACTMonika Laszkowska, MD
LaszkowM@mskcc.org212-639-6857
CONTACTXiang Shu, PhD
ShuX@mskcc.org646-227-3658
PRINCIPAL_INVESTIGATORMonika Laszkowska, MD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026